Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Study to Investigate the Efficacy and Safety of the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma

NCT04733183 is registered in ClinicalTrials.gov with Philogen S.p.A. as lead sponsor.

NCT NCT04733183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04733183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Study to Investigate the Efficacy and Safety of the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma
Lead sponsor
Philogen S.p.A.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 28, 2020
Completion date
December 31, 2025
Enrollment
98 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

soft tissue sarcoma